>Neil Rodrigues, Ph.D., Assistant Professor at Boston University, takes a novel approach to hematopoietic stem cell expansion. Rather than utilizing on conventional growth factors, Dr. Rodrigues employs small molecule compounds that promote stem cell division without differentiation. This approach has several advantages, including relatively low cost and the ability to target specific cell populations. He also investigates small molecule compounds that target leukemic stem cells which can sustain leukemia and cause disease relapse. Ultimately, this work could lead to new strategies that broaden the utility of stem cell therapy beyond traditional blood cancers and promote hematopoietic stem cell engraftment in patients immediately post-transplantation, when they are most prone to infection.
Additional information about the BD Biosciences Grant Program is available at http://www.bdbiosciences.com/grant
About the BD Biosciences Research Grant Program
BD Biosciences' Research Grant Program aims to reward and enable important research by providing vital funding for scientists pursuing innovative experiments to advance the scientific understanding of disease. The grant submissions are judged by a distinguished research panel of non-affiliated scientists. Through its grant program, BD Biosciences supports innovation in research and development as well as help enable the next generation of scientific breakthroughs.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental iPage: 1 2 3 4 Related biology technology :1
. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 20082
. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences3
. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update4
. Milestone Biosciences, LLC Further Strengthens Executive Management Team5
. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update6
. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America7
. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies8
. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference9
. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo10
. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium11
. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)